CheckMate 648: Expanded Analysis of First-line Nivolumab + CT vs Nivolumab/Ipilimumab vs CT in Advanced Esophageal Squamous Cell Carcinoma

June 3-7, 2022; Chicago, Illinois
Improved survival with nivolumab + chemotherapy and nivolumab + ipilimumab vs chemotherapy alone in previously untreated patients with advanced esophageal squamous cell carcinoma and at least 1% PD-L1 expression assessed by either tumor cell staining or CPS.
Format: Microsoft PowerPoint (.ppt)
File Size: 157 KB
Released: June 13, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Related Content

Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)

person default Nina Beri, MD Released: August 3, 2022

Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)

Samuel Klempner, MD Released: July 21, 2022

Data on dostarlimab for locally advanced, mismatch repair-deficient rectal cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

CAIRO5: FOLFOXIRI + bevacizumab vs FOLFOX/FOLFIRI + bevacizumab in initially unresectable colorectal liver metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings